Major brands at fantastic prices
In a world first, Sharp Corporation developed a device equipped with Plasmacluster technology, which exposed an airborne novel coronavirus (SARS-CoV-2) to Plasmacluster ions for approximately 30 seconds*3, and demonstrated that the virus infectious titer*4 was reduced more than 90%. This achievement was accomplished in collaboration with Professor Jiro Yasuda of the National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University, Professor Asuka Nanbo (a Board member of the Japanese Society for Virology) of the same institution, and Professor Hironori Yoshiyama of the Department of Microbiology, Shimane University Faculty of Medicine (also a Board member of the Japanese Society for Virology), and in cooperation with Nagasaki University, an internationally respected authority on infectious disease research.
In December 2019
An outbreak of “Coronavirus disease 2019 (COVID-19)” caused by a novel coronavirus (SARS-CoV-2) was reported, and by August 2020, more than 25 million people have been infected with SARS-CoV-2 and more than 840,000 individuals died of this infectious disease in a world*5. This outbreak represents an urgent problem facing society, and demands that immediate countermeasures be taken across a wide range of fields.
Sharp demonstrated the effectiveness of Plasmacluster technology against feline (cat) coronavirus, a member of the Coronaviridae family*6. In the following year, 2005, Sharp also demonstrated its effectiveness against the original SARS coronavirus*7 (SARS-CoV), which caused the outbreak (2002-2003) and genetically similar to the novel coronavirus (SARS-CoV-2). Now, Sharp has demonstrated its effectiveness against SARS-CoV-2 in airbornedroplets.
Sharp has promoted academic marketing*8 to demonstrate the effectiveness of Plasmacluster technology, working in collaboratio with independent third-party research organizations around the world. Thus far, numerous independent research organizations have proven its clinical efficacy in suppressing the activity of harmful substances including new pandemic influenza viruses, drug-resistant bacteria, and mite allergens, as well as in reducing bronchial inflammation levels*9 in children with asthma. At the same time, the safety of Plasmacluster ions has also been confirmed*10. Sharp will continue to contribute to society by conducting a wide range of studies demonstrating the effectiveness of Plasmacluster technology.
Unit 16 Anglo Industrial Park, Fishponds Road, Wokingham, RG41 2AN
VAT Number: GB943254034
Company Registration Number: 07356469